(Q28278125)

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The genomic landscapes of human breast and colorectal cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The role of companion diagnostics in the development and use of mutation-targeted cancer therapies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Sequencing technologies - the next generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Mutational evolution in a lobular breast tumour profiled at single nucleotide resolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A small-cell lung cancer genome with complex signatures of tobacco exposure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A comprehensive catalogue of somatic mutations from a human cancer genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Single-molecule sequencing of an individual human genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genome resequencing and genetic variation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Targeted capture and massively parallel sequencing of 12 human exomes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A HapMap harvest of insights into the genetics of common disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Common genetic variation and human traits

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genomewide association studies--illuminating biologic pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genetic risk prediction--are we there yet?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Inherited susceptibility to common cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genetic mapping in human disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Finding the missing heritability of complex diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

MicroRNAs make big impression in disease after disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A loss-of-function RNA interference screen for molecular targets in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Compensatory IKKalpha activation of classical NF-kappaB signaling during IKKbeta inhibition identified by an RNA interference sensitization screen

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

RNAi screen for rapid therapeutic target identification in leukemia patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Synthetic lethal interaction between oncogenic KRAS dependency and STK33 suppression in human cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A gene expression signature associated with "K-Ras addiction" reveals regulators of EMT and tumor cell survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genome-wide association scan of tag SNPs identifies a susceptibility locus for lung cancer at 15q25.1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A variant associated with nicotine dependence, lung cancer and peripheral arterial disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Predicting the future for people with lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

MicroRNA signature predicts survival and relapse in lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Diagnostic assay based on hsa-miR-205 expression distinguishes squamous from nonsquamous non-small-cell lung carcinoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Epidermal growth factor receptor mutations in lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Detection of mutations in EGFR in circulating lung-cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Identification of novel isoforms of the EML4-ALK transforming gene in non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Inhibition of ALK signaling for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Mutations in the LKB1 tumour suppressor are frequently detected in tumours from Caucasian but not Asian lung cancer patients

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The LKB1-AMPK pathway: metabolism and growth control in tumour suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Understanding the Warburg effect: the metabolic requirements of cell proliferation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Somatic mutations affect key pathways in lung adenocarcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Comparative lesion sequencing provides insights into tumor evolution

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genetic prognostic and predictive markers in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genome-wide association scan identifies a colorectal cancer susceptibility locus on chromosome 8q24.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A genome-wide association study identifies colorectal cancer susceptibility loci on chromosomes 10p14 and 8q23.3

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

RETRACTED: A genomic approach to colon cancer risk stratification yields biologic insights into therapeutic opportunities

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Comprehensive pharmacogenetic analysis of irinotecan neutropenia and pharmacokinetics

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

K-ras mutations and benefit from cetuximab in advanced colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Targeting EGFR in colorectal cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genome-wide association study identifies novel breast cancer susceptibility loci

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Common variants on chromosomes 2q35 and 16q12 confer susceptibility to estrogen receptor-positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Common variants on chromosome 5p12 confer susceptibility to estrogen receptor–positive breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The genetics of the p53 pathway, apoptosis and cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Molecular portraits of human breast tumours

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

DNA microarrays in breast cancer: the promise of personalised medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Gene-expression signatures in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Phase 0 clinical trial of the poly (ADP-ribose) polymerase inhibitor ABT-888 in patients with advanced malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The relative contribution of point mutations and genomic rearrangements in BRCA1 and BRCA2 in high-risk breast cancer families

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Synthetic lethality--a new direction in cancer-drug development

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

CYP2D6 and tamoxifen: DNA matters in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Active surveillance for early-stage prostate cancer: review of the current literature

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Identification of seven new prostate cancer susceptibility loci through a genome-wide association study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Functional enhancers at the gene-poor 8q24 cancer-linked locus.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The 8q24 cancer risk variant rs6983267 shows long-range interaction with MYC in colorectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Long-range enhancers on 8q24 regulate c-Myc

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The common colorectal cancer predisposition SNP rs6983267 at chromosome 8q24 confers potential to enhanced Wnt signaling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Cumulative association of five genetic variants with prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Multiple newly identified loci associated with prostate cancer susceptibility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Multiple loci identified in a genome-wide association study of prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Fine mapping and functional analysis of a common variant in MSMB on chromosome 10q11.2 associated with prostate cancer susceptibility

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Characterization of TMPRSS2-ETS gene aberrations in androgen-independent metastatic prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Absence of TMPRSS2:ERG fusions and PTEN losses in prostate cancer is associated with a favorable outcome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Recurrent gene fusions in prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

TMPRSS2-ERG and PTEN loss in prostate cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Prostate cancer genomics: towards a new understanding

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genetic risk factors for melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genome-wide association study identifies three loci associated with melanoma risk

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A multi-marker assay to distinguish malignant melanomas from benign nevi

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Analysis of the tyrosine kinome in melanoma reveals recurrent mutations in ERBB4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Somatic activation of KIT in distinct subtypes of melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Classification and diagnostic prediction of cancers using gene expression profiling and artificial neural networks

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Common variations in BARD1 influence susceptibility to high-risk neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Prediction of clinical outcome using gene expression profiling and artificial neural networks for patients with neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Expression profiling using a tumor-specific cDNA microarray predicts the prognosis of intermediate risk neuroblastomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Prediction of clinical outcome and biological characterization of neuroblastoma by expression profiling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Prognostic significance of gene expression profiles of metastatic neuroblastomas lacking MYCN gene amplification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Customized Oligonucleotide Microarray Gene Expression–Based Classification of Neuroblastoma Patients Outperforms Current Clinical Risk Stratification

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Oncogenic mutations of ALK kinase in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Activating mutations in ALK provide a therapeutic target in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Somatic and germline activating mutations of the ALK kinase receptor in neuroblastoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The anaplastic lymphoma kinase in the pathogenesis of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A biologic definition of Burkitt's lymphoma from transcriptional and genomic profiling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Molecular diagnosis of Burkitt's lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The biology of human lymphoid malignancies revealed by gene expression profiling.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Stromal gene signatures in large-B-cell lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Oncogenic CARD11 mutations in human diffuse large B cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Mutations of multiple genes cause deregulation of NF-kappaB in diffuse large B-cell lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Frequent inactivation of A20 in B-cell lymphomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Is NF-kappaB a good target for cancer therapy? Hopes and pitfalls

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

An inhibitor of NEDD8-activating enzyme as a new approach to treat cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Molecular diagnosis of the hematologic cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Attacking cancer at its foundation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Sequential ABL kinase inhibitor therapy selects for compound drug-resistant BCR-ABL mutations with altered oncogenic potency

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Targeting cancer with small molecule kinase inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

AP24534, a pan-BCR-ABL inhibitor for chronic myeloid leukemia, potently inhibits the T315I mutant and overcomes mutation-based resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Structural and functional alterations of FLT3 in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Identification of driver and passenger mutations of FLT3 by high-throughput DNA sequence analysis and functional assessment of candidate alleles.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

High throughput digital quantification of mRNA abundance in primary human acute myeloid leukemia samples

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genomic analysis reveals few genetic alterations in pediatric acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Recurring mutations found by sequencing an acute myeloid leukemia genome

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Genome-wide interrogation of germline genetic variation associated with treatment response in childhood acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Loci on 7p12.2, 10q21.2 and 14q11.2 are associated with risk of childhood acute lymphoblastic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A role for JAK2 mutations in myeloproliferative diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Mutation in TET2 in myeloid cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Therapeutic potential of JAK2 inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

ZAP-70 expression identifies a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome, and distinct gene expression profile

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Relative value of ZAP-70, CD38, and immunoglobulin mutation status in predicting aggressive disease in chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

MicroRNAs in cancer: small molecules with a huge impact

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Causes and consequences of microRNA dysregulation in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Integration of Molecular Profiling into the Lung Cancer Clinic

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Targeting PI3K signalling in cancer: opportunities, challenges and limitations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Targeting the phosphoinositide 3-kinase pathway in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Use of electronic health records in U.S. hospitals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Personally controlled online health data--the next big thing in medical care?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The cancer biomarker problem

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Validating, augmenting and refining genome-wide association signals

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

DNA sequence and analysis of human chromosome 8

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

The diploid genome sequence of an Asian individual

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

A highly annotated whole-genome sequence of a Korean individual

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Comprehensive resequence analysis of a 136 kb region of human chromosome 8q24 associated with prostate and colon cancers

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Human genomics: The genome finishers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Polygenes, risk prediction, and targeted prevention of breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

An agenda for personalized medicine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Misconceptions about the use of genetic tests in populations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRCLINONC.2010.41

Identification of FGFR4-activating mutations in human rhabdomyosarcomas that promote metastasis in xenotransplanted models

31 March 2020

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20351699

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Realizing the promise of personalized medicine

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/20351699

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1038/NRCLINONC.2010.41

1 reference

Consolidated OpenCitations Corpus – April 2017

2566615

2566615

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

1 reference